

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,189,713 B2
APPLICATION NO. : 10/502255
DATED : March 13, 2007
INVENTOR(S) : Alvaro et al.

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 57, claim 10, line 13 should read:

-- dro-pyrrolo[1,2-a]pyrazin-2yl)-piperidine-1-car --

Column 57, claim 14, line 41 should read:

-- CH, A is C(O), X is CH₂, R is independently a halogen or --

Column 57, claim 17, line 53 should read:

-- 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-((8aS-6-oxo- --

Column 57, claim 19, line 64 should read:

-- from fluoxetine, citalopram, fenoxetone, fluvoxamine, --

Column 58, claim 26, line 33 should read:

-- schizoaffective disorder of the depressed type --

Column 60, claim 61, line 50 should read:

-- [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]- --

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,189,713 B2
APPLICATION NO. : 10/502255
DATED : March 13, 2007
INVENTOR(S) : Alvaro et al.

Page 2 of 2


It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 62, claim 71, line 36 should read:

-- carboxylic acid[1-(R)-(3,5-bis-trifluoromethyl-phenyl)- --

Signed and Sealed this

Ninth Day of October, 2007

A handwritten signature in black ink, appearing to read "Jon W. Dudas". The signature is stylized with a large, looped initial "J" and a distinct "D".

JON W. DUDAS
Director of the United States Patent and Trademark Office